Manipal Health IPO allotment: QIB demand, Aug 5

Manipal Health Enterprises’ IPO is a key retail discussion point on social media this week as investors track the allotment timeline, QIB subscription and the August 5 listing on NSE and BSE. Posts across Reddit and market forums indicate the basis of allotment is expected to be finalised on August 3, 2026, after bidding closed on July 31. The public issue is widely described as having received a “healthy” overall response at 4.92 times subscription. The most discussed segment is the Qualified Institutional Buyers (QIB) book, which led demand and is being cited in the 8.25x to 8.54x range across different updates. With allotment day here, the focus has shifted from applying to verifying status via the registrar and exchange portals. Separately, a muted grey market premium (GMP) of around 2% is being referenced in the social chatter, with some users noting a recent downtrend in GMP ahead of listing. Below is a fact-only guide based on what is circulating in public posts, including dates, subscription snapshots, and the steps to check allotment.

Allotment day: what investors expect on August 3

Social media updates repeatedly point to August 3, 2026 as the expected date for finalising the basis of allotment for Manipal Health Enterprises. Investors are primarily watching for two outcomes today: whether they received shares, and what quantity was allotted. The discussion is practical rather than speculative, with users sharing official portal links and step-by-step checks. Many posts also connect allotment timing to downstream steps such as refunds and demat credit, because that is when the status becomes actionable. The expectation of “today” is tied to the standard IPO process referenced in the timeline shared online. At the same time, several sources label these dates as tentative, meaning changes are possible. That caveat is being repeated in some posts and is worth keeping in mind. For most applicants, clarity comes through the registrar portal first and then reflects through DP or bank messaging later.

Key dates: IPO open, close, allotment, listing

The widely shared timeline pegs bidding to a three-day window ending July 31, 2026, with listing expected on August 5, 2026. Multiple posts state the shares are scheduled to list on both the NSE and BSE on August 5. In between, August 4 is being referenced as the day for refunds and demat credit. This sequencing is central to the online conversation because it sets expectations for when blocked funds may be released for non-allottees. Some posts mention refunds initiation on August 4, while another line mentions refunds initiation on August 3, indicating minor inconsistency in circulating summaries. The core message remains consistent: allotment on August 3, credits and refunds around August 4, listing on August 5. Investors tracking quick turnaround are mostly focused on whether shares appear in demat by August 4. Here is the consolidated schedule being shared most frequently.

Subscription snapshot: overall 4.92x and QIB-led demand

Investors are sharing the final subscription figure of 4.92 times for the IPO at close. The strongest traction is repeatedly attributed to the QIB portion, which is being reported at 8.25x in some posts and 8.54x in others. This difference appears to be due to separate updates circulating from different sources, rather than a change in the underlying process. The non-institutional investor (NII) portion is being cited at 1.02x in the same set of posts. Retail subscription details are not consistently repeated across the context, so online debate is centred more on institutions than on retail oversubscription. There is also a mention that anchor investors raised Rs 4,167 crore, which is being used by some users to interpret institutional interest. Another detail floating around is “QIB quota 4.48%”, though the context does not clarify the basis of that percentage. For quick reference, here is the subscription summary as discussed.

“QIB list” search trend: what is and is not available

A common query on social media is the “QIB list”, usually meaning the names of institutional bidders. In the current circulating context, the posts provide QIB subscription multiples but do not provide a confirmed list of QIB names. What is mentioned is that the QIB book led the subscription and that anchors raised Rs 4,167 crore. That has encouraged users to look for more detail, but the information shared in these posts is limited to aggregated subscription data and broad labels like QIB and NII. As a result, investors trying to find a QIB-by-name breakdown are often redirected to official filings and disclosures rather than social summaries. The practical takeaway for allotment day is that QIB demand influences overall book strength, but it does not change the allotment checking process for retail applicants. The “QIB list” phrase is therefore more of a search trend than a confirmed dataset in the shared discussion. If you see a list circulating without source links, treat it cautiously. For now, the fact pattern in the posts is limited to subscription multiples and anchor collection.

Offer size and structure: what posts highlight

The IPO size being discussed is Rs 9,275 crore. Several posts describe the issue as comprising a fresh issue of Rs 8,000 crore and an offer for sale (OFS) of Rs 1,275.2 crore. The price band is being shared as Rs 560 to Rs 590 per share, with cut-off often referenced at Rs 590. These details are central because they influence application amounts and expectations around retail participation. The issue is also described as being backed by Temasek and Ranjan Pai, which is frequently repeated in the context. Some posts label it a Bengaluru-based hospital chain and refer users to the company website. Beyond these basics, the social conversation stays focused on allotment and listing rather than business metrics. Users are also comparing this IPO’s response with other recent issues, but those comparisons are not detailed with numbers in the context. The offer structure points are mainly being used to summarise the deal rather than to make valuation claims.

How to check allotment on KFin Technologies (registrar)

The most repeated method for checking Manipal Health IPO allotment is through KFin Technologies, which is cited as the registrar portal. Users are posting the direct path as ipostatus.kfintech.com and advising applicants to keep PAN and application details ready. The step flow being shared is straightforward and designed for first-time IPO applicants. First, visit the KFin Technologies IPO allotment portal. Second, select “Manipal Health Enterprises Ltd.” from the dropdown menu. Third, choose an identification option such as PAN, Application Number, or DP ID/Client ID. Fourth, enter the required information exactly as used in the IPO application. Fifth, click “Submit” to view the allotment status. Investors are also reminding each other to retry later if the portal is slow on allotment day due to traffic.

How to check allotment on BSE and NSE portals

Alongside the registrar site, investors are also using exchange pages to check allotment status. For BSE, the commonly shared link is the BSE IPO allotment page, where users are instructed to select “Equity” under issue type and then choose Manipal Health Enterprises from the dropdown. Applicants then enter application number or PAN to fetch status. For NSE, posts reference the IPO bid and allotment checking page, where users select “Equity”, pick the company name, and enter the application number and PAN. These steps are being posted as alternatives when one site is down or slow. The process is similar across portals, which reduces confusion for applicants checking for the first time. Most users recommend starting with the registrar portal because it is closest to the allotment processing system. Exchange portals, however, are useful cross-checks on the same day. If there is a mismatch, investors generally wait for the registrar view to stabilise.

Demat credit and refunds: what to watch on August 4

The next milestone being discussed is August 4, 2026 for demat credit and refunds. Social posts describe this as the day when allotted shares may show up in the demat account and when refunds or unblocking of funds may occur for those who did not receive allotment. This is important for investors planning cash management around listing day. Some updates place refund initiation on August 4, while one line mentions August 3, so timelines in posts are not perfectly uniform. The practical expectation remains that settlement actions happen after allotment finalisation. Many users are advising each other to monitor both the demat account and bank messages rather than relying on only one channel. If shares are credited on August 4, it typically gives investors a full day to prepare ahead of the August 5 listing. If credits appear later, it can compress the time window to plan orders. Either way, the status check on August 3 is the starting point.

Listing on August 5 and the GMP discussion online

The listing date being repeated in posts is August 5, 2026, with a debut planned on both BSE and NSE. Social media chatter includes references to a muted grey market premium (GMP) of around 2%, which some users interpret as signalling limited listing gains. There are also comments about a downtrend in GMP in recent sessions, though specific time-series numbers are not provided in the context. Because GMP is informal and not an exchange indicator, most posts treat it as sentiment rather than a definitive forecast. The more actionable items for investors remain allotment confirmation, demat credit, and understanding listing-day mechanics. Applicants who receive shares are discussing whether to hold or sell on listing day, but the posts do not provide firm guidance or targets. The best-supported fact in the shared discussion is simply the schedule: allotment August 3 and listing August 5. Investors should therefore focus on verifying allocation and ensuring their trading accounts are ready before the debut. Any expectations on listing gains should be treated cautiously when based solely on GMP chatter.